Pharmacyte Biotech Inc (PMCB) Stock Price, Quote & News

Company Profile

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other soli...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 595 2850

Fax: 917 595 2851

Website: pharmacyte.com

Address:

3960 Howard Hughes Parkway, Suite 500, Las Vegas, United States

Dfastpitchchic5 Jan. 13 at 5:19 PM

$QCLS $PMCB

0 · Reply

Dfastpitchchic5 Jan. 13 at 3:05 PM

$PMCB

0 · Reply

Dfastpitchchic5 Jan. 12 at 2:41 PM

$QCLS $PMCB

0 · Reply

BreadGarlichouse Jan. 12 at 12:21 PM

$PMCB seeing some fud - makes me more bullish $KALA too

0 · Reply

Pistol_Pete_P Jan. 12 at 7:21 AM

$PMCB scam

0 · Reply

Quantumhater Jan. 10 at 10:27 AM

$PMCB Do your own research about Silverman's and Iroquois history. They take over Stocks and create value not for all shareholders but for themselves. There are lots of warrants for $PMCB at 95 cents so with their buys I think they are just trying to create momentum to dump the exercised warrant shares on retail.

1 · Reply

matans844 Jan. 10 at 4:32 AM

$QCLS Notice that $PMCB holds 74% of the $QCLS float [1] and two insiders bought shares in it last week: Joshua Silverman (CEO) [2] and Jonathan Schechter [3]. This catalyst helped drive $PMCB up by +19.44% on the week, and +44.13% from Wednesday’s low (0.68) to Thursday’s high (0.9801). Mr. Silverman is also the Executive Chairman of the Board at $QCLS [4], so buying more of $PMCB now means, at the very least, that $QCLS is not headed to past lows. Links: [1] https://www.sec.gov/Archives/edgar/data/1157075/000168316825008515/xslSCHEDULE_13D_X01/primary_doc.xml [2] https://www.sec.gov/Archives/edgar/data/1524858/000168316826000148/xslF345X05/ownership.xml [3] https://www.sec.gov/Archives/edgar/data/1619259/000168316826000147/xslF345X05/ownership.xml [4] https://finance.yahoo.com/quote/QCLS/profile/

1 · Reply

Dfastpitchchic5 Jan. 9 at 4:33 PM

$QCLS $PMCB

0 · Reply

kagankocaoglu Jan. 8 at 11:30 PM

$QCLS do you guyz expect for $PMCB merger? they have tons of qcls warrants

0 · Reply

BreadGarlichouse Jan. 8 at 9:57 PM

$PMCB I am all in. W or L ?

0 · Reply

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

FEMY

Sep 2, 2025, 9:20 AM EDT - 4 months ago

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

Aug 20, 2025, 9:15 AM EDT - 5 months ago

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

Aug 18, 2025, 9:15 AM EDT - 5 months ago

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

May 21, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024, 9:00 AM EDT - 1 year ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

Nov 15, 2023, 8:30 AM EST - 2 years ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

FEMY

Oct 31, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

Jun 15, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Announces Final Results of Tender Offer

May 11, 2023, 8:30 AM EDT - 2 years ago

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

Feb 2, 2023, 9:00 AM EST - 3 years ago

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

Oct 7, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Aug 15, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Jul 28, 2022, 12:49 PM EDT - 3 years ago

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Jul 28, 2022, 9:00 AM EDT - 3 years ago

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

Jul 21, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

Jul 19, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Jul 11, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

Jul 11, 2022, 6:00 AM EDT - 3 years ago

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 3:16 PM EDT - 3 years ago

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

Jun 23, 2022, 9:00 AM EDT - 3 years ago

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

Jun 15, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

Jun 13, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

Jun 9, 2022, 9:00 AM EDT - 3 years ago

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jun 8, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

Jun 2, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

May 23, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

May 11, 2022, 9:00 AM EDT - 4 years ago

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

Apr 27, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

Apr 19, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

Apr 13, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

Apr 5, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

Mar 22, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

Mar 16, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Feb 22, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

Feb 14, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

Jan 7, 2022, 2:59 AM EST - 4 years ago

Is This A Good Time To Invest In PharmaCyte?

Jan 6, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

Jan 4, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

Dec 28, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

Dec 15, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

Dec 8, 2021, 10:16 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

Nov 30, 2021, 1:05 AM EST - 4 years ago

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

Nov 12, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

Sep 27, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

Sep 21, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Sep 16, 2021, 1:51 PM EDT - 4 years ago

Why Are PharmaCyte Shares Moving Higher On Thursday?

Sep 16, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Sep 9, 2021, 8:57 AM EDT - 4 years ago

Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?

Dfastpitchchic5 Jan. 13 at 5:19 PM

$QCLS $PMCB

0 · Reply

Dfastpitchchic5 Jan. 13 at 3:05 PM

$PMCB

0 · Reply

Dfastpitchchic5 Jan. 12 at 2:41 PM

$QCLS $PMCB

0 · Reply

BreadGarlichouse Jan. 12 at 12:21 PM

$PMCB seeing some fud - makes me more bullish $KALA too

0 · Reply

Pistol_Pete_P Jan. 12 at 7:21 AM

$PMCB scam

0 · Reply

Quantumhater Jan. 10 at 10:27 AM

1 · Reply

matans844 Jan. 10 at 4:32 AM

1 · Reply

Dfastpitchchic5 Jan. 9 at 4:33 PM

$QCLS $PMCB

0 · Reply

kagankocaoglu Jan. 8 at 11:30 PM

$QCLS do you guyz expect for $PMCB merger? they have tons of qcls warrants

0 · Reply

BreadGarlichouse Jan. 8 at 9:57 PM

$PMCB I am all in. W or L ?

0 · Reply

Dfastpitchchic5 Jan. 8 at 9:47 PM

$AEON $QCLS $PMCB $YYAI

2 · Reply

Dfastpitchchic5 Jan. 8 at 9:46 PM

$YYAI $KIDZ $QCLS $PMCB

0 · Reply

Dfastpitchchic5 Jan. 8 at 9:44 PM

$PMCB $QCLS

0 · Reply

Dfastpitchchic5 Jan. 8 at 9:43 PM

$QCLS $PMCB

0 · Reply

SPYmyQQQ Jan. 8 at 8:44 PM

🎯 Target Hit 🏁 📨 From Dec 23, 2025 💊 $PMCB 💵 Entry: $0.8224 ✅ Ext: $0.9764 💰 P/L: +18.73% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

DeltaRacer Jan. 8 at 7:19 PM

$PMCB whats the news for the move? Any info?

1 · Reply

JJBurch Jan. 8 at 7:14 PM

$PMCB what do we think? Some $QCLS news imminent? Seems most likely Awaiting my ALL IN play (which means only that it’s my largest investment) of $MIGI to start. That one is so close too

1 · Reply

Dieseld28 Jan. 8 at 4:59 PM

$ZNTL $PMCB

0 · Reply

Dfastpitchchic5 Jan. 8 at 3:22 PM

$PMCB @$QCLS

0 · Reply

SPYmyQQQ Jan. 8 at 1:32 PM

🎯 Target Hit 🏁 📨 From Jan 5, 2026 💊 $PMCB 💵 Entry: $0.7740 ✅ Ext: $0.9060 💰 P/L: +17.05% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

JJBurch Jan. 8 at 1:21 PM

$QCLS feels pretty damn strong to me. And with $PMCB also on the move. Prepare for bio asset sale info $MIGI ready to fly. Any day now it goes $20++ Big day ahead

0 · Reply

AZOZ Jan. 8 at 12:31 PM

$PMCB Insider activity!

0 · Reply

Market Cap	9.10M
Revenue (ttm)	0.00
Net Income (ttm)	30.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	244,100
Avg Vol	4,273,676
Day's Range	N/A - N/A
Shares Out	10.13M
Stochastic %K	76%
Beta	0.04
Analysts	Strong Buy
Price Target	N/A